

STRIDES PHARMA ASIA PTE LIMITED
BALANCE SHEET AS AT MARCH 31, 2022

Amount in USD

	Note No.	31-Mar-22	31-Mar-21
I. Equity and Liabilities			
1. Shareholders' Funds			
(a) Share Capital	1	175,329,360	175,329,360
(b) Reserves and Surplus	2	23,353,276	23,353,363
		198,682,636	198,682,723
2. Share application money pending allotment		-	-
3. Non-current liabilities			
(a) Long-term borrowings		-	-
4. Current liabilities			
(a) Short-term borrowings		-	-
(b) Trade payables	3	8,235,079	8,451,236
(c) Other Current Liabilities	4	3,608,987	4,360,225
(d) Short-term provisions	5	52,569	52,569
		11,896,635	12,864,030
TOTAL		210,579,271	211,546,753
II. Assets			
(1) Non-Current Assets			
(a) Non- current investments	6	209,826,584	210,742,158
		209,826,584	210,742,158
(2) Current assets			
(a) Cash and Cash Equivalents	7	295,419	319,241
(b) Short-term Loans and Advances	8	457,268	485,354
		752,687	804,595
TOTAL		210,579,271	211,546,753

STRIDES PHARMA ASIA PTE LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2022

Amount in USD

	Particulars	Note No.	31-Mar-22	31-Mar-21
I	Other Income	9	43,294	1,967,493
II	Total Revenue		43,294	1,967,493
III	Expenses			
	Other Expenses	10	39,820	160,584
	Finance costs	11	3,561	1,679,518
	Total		43,381	1,840,102
IV	Profit / (Loss) before exceptional items and taxes		(87)	127,391
V	Exceptional expenses - Acquisition related costs		-	-
VI	Profit / (Loss) before taxes		(87)	127,391
VII	Tax Expense:			
	(1) Current tax		-	-
	(2) Deferred tax Liability / (Asset)		-	-
VIII	Profit / (Loss) for the year after tax		(87)	127,391

STRIDES PHARMA ASIA PTE LIMITED
Notes forming part of the financial statements

Note

No.

1 Share capital

Amount in USD

Particulars	31-Mar-22	31-Mar-21
Issued, subscribed and fully paid-up		
Equity share capital	175,329,360	175,329,360
Preference share capital	-	-
Total	175,329,360	175,329,360

STRIDES PHARMA ASIA PTE LIMITED
Notes forming part of the financial statements

Note

No.

2 Reserves and surplus		Amount in USD	
Particulars	31-Mar-22	31-Mar-21	
Securities Premium Account			
Opening Balance	-	-	
Add : Premium on shares issued during the year	-	-	
Closing balance	-	-	
Foreign Currency Translation Reserve			
Adjustment	-	-	
	-	-	
Surplus in Statement of Profit and Loss			
Opening Balance	23,353,363	28,032,672	
Translation adjustment			
Add: Profit / (Loss) for the year	(87)	127,391	
Less: Equity dividend	-	(4,806,700)	
Less: Preference dividend	-	-	
Closing balance	23,353,276	23,353,363	
Total	23,353,276	23,353,363	
Long-term borrowings		Amount in USD	
Particulars	31-Mar-22	31-Mar-21	
Secured			
- Term Loans from banks	-	-	
Total	-	-	
Short-term borrowings		Amount in USD	
Particulars	31-Mar-22	31-Mar-21	
Short term borrowings	-	-	
Total	-	-	
3 Trade payables		Amount in USD	
Particulars	31-Mar-22	31-Mar-21	
Other than acceptances	8,235,079	8,451,236	
Total	8,235,079	8,451,236	
4 Other current liabilities		Amount in USD	
Particulars	31-Mar-22	31-Mar-21	
Current maturities of long term borrowings	-	-	
Interest accrued but not due	-	-	
Payable to group entities	3,608,657	2,644,005	
Dividend Payable	-	1,704,000	
Other payables:			
- Statutory remittances	330	12,220	
Total	3,608,987	4,360,225	
5 Short-term provisions		Amount in USD	
Particulars	31-Mar-22	31-Mar-21	
Provision for employee benefits:			
- Compensated absences	-	-	
Provision - Others:			
- Provision for tax (net of advance tax)	52,569	52,569	
Total	52,569	52,569	

6 Non - current investments **Amount in USD**

Particulars	31-Mar-22	31-Mar-21
Strides Pharma Global Pte Limited	202,861,479	204,861,479
Stelis Biopharma (Malaysia) SDN BHD	1,376,186	1,376,186
Trinity Pharma (Pty) Limited	4,471,472	4,471,472
Arrow Pharma Pte Limited	1,117,447	33,021
Strides Specialties (Holdings) Limited	-	-
Total	209,826,584	210,742,158

7 Cash and cash equivalents **Amount in USD**

Particulars	31-Mar-22	31-Mar-21
Bank balance	295,419	319,241
Fixed deposit with bank	-	-
Total	295,419	319,241

8 Short-term loans and advances **Amount in USD**

Particulars	31-Mar-22	31-Mar-21
Unsecured, considered good		
Loans and advances to employees	-	-
Loans and advances to suppliers	-	-
Loans and advances to Group entities	457,268	485,354
Balances with government authorities:		
- VAT credit receivable	-	-
- Advance tax	-	-
Prepaid Expenses	-	-
Total	457,268	485,354

STRIDES PHARMA ASIA PTE LIMITED
Notes forming part of the financial statements

Note

No

9 Other Income		USD	
Particulars	31-Mar-22	31-Mar-21	
Profit/(Loss) on sale of investment	-	1,873,512	
Other Income- Guarantee commission	6,401	2,652	
Exchange fluctuation gain (net)	8,671	63,194	
Interest Income	28,222	28,135	
Total	43,294	1,967,493	

10 Other Expenses		USD	
Particulars	31-Mar-22	31-Mar-21	
Membership fees and subscription	635	646	
Professional fees	6,893	13,467	
Rates and taxes	500	119,116	
Payment to Auditors - For Statutory Audit	20,773	20,069	
Director sitting fees	6,000	5,963	
Support service expenses- Arcolab	1,317	1,322	
Others	3,702	1	
Total	39,820	160,584	

11 Finance Cost		USD	
Particulars	31-Mar-22	31-Mar-21	
Interest	-	1,676,714	
Bank Charges & Commission	3,561	2,804	
Total	3,561	1,679,518	